Rallybio Corp. (RLYB)
17.03
+0.16
(+0.92%)
USD |
NASDAQ |
Sep 14, 10:32
Rallybio 1 Year Total Returns (Daily) : 256.6% for Sept. 11, 2026
1 Year Total Returns (Daily) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| September 11, 2026 | 256.6% |
| September 10, 2026 | 249.0% |
| September 09, 2026 | 264.0% |
| September 08, 2026 | 249.5% |
| September 04, 2026 | 261.0% |
| September 03, 2026 | 265.3% |
| September 02, 2026 | 279.8% |
| September 01, 2026 | 288.8% |
| August 31, 2026 | 291.1% |
| August 28, 2026 | 275.1% |
| August 27, 2026 | 255.3% |
| August 26, 2026 | 253.7% |
| August 25, 2026 | 262.8% |
| August 24, 2026 | 235.5% |
| August 21, 2026 | 254.2% |
| August 20, 2026 | 242.2% |
| August 19, 2026 | 273.5% |
| August 18, 2026 | 235.5% |
| August 17, 2026 | 251.8% |
| August 14, 2026 | 289.0% |
| August 13, 2026 | 296.0% |
| August 12, 2026 | 311.7% |
| August 11, 2026 | 312.0% |
| August 10, 2026 | 291.0% |
| August 07, 2026 | 295.3% |
| Date | Value |
|---|---|
| August 06, 2026 | 283.5% |
| August 05, 2026 | 268.2% |
| August 04, 2026 | 277.1% |
| August 03, 2026 | 272.7% |
| July 31, 2026 | 328.2% |
| July 30, 2026 | 318.5% |
| July 29, 2026 | 324.3% |
| July 28, 2026 | 300.9% |
| July 27, 2026 | 308.8% |
| July 24, 2026 | 289.1% |
| July 23, 2026 | 287.3% |
| July 22, 2026 | 325.5% |
| July 21, 2026 | 357.2% |
| July 20, 2026 | 385.8% |
| July 17, 2026 | 351.4% |
| July 16, 2026 | 361.6% |
| July 15, 2026 | 387.0% |
| July 14, 2026 | 376.5% |
| July 13, 2026 | 389.0% |
| July 10, 2026 | 396.5% |
| July 09, 2026 | 343.3% |
| July 08, 2026 | 283.3% |
| July 07, 2026 | 475.4% |
| July 06, 2026 | 490.6% |
| July 02, 2026 | 512.2% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Beam Therapeutics, Inc. | 11.32% |
| C4 Therapeutics, Inc. | 28.57% |
| Cullinan Therapeutics, Inc. | 211.0% |
| Q32 Bio, Inc. | 490.4% |
| Arrowhead Pharmaceuticals, Inc. | 178.8% |